Travoprost

USP/1673001 - United States Pharmacopeia (USP) Reference Standard

Synonym: Travoprost solution

CAS Number: 157283-68-6
Empirical Formula (Hill Notation): C₂₆H₃₅F₃O₆
Molecular Weight: 500.55
Linear Formula: C₂₆H₃₅F₃O₆
Product Type: Chemical

Catalog Number	PKG Qty.	Price	Quantity


45-1673001-3ML	3 mL	$436.00 1/EA		Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

API family	travoprost
application(s)	pharmaceutical (small molecule)
format	neat
grade	pharmaceutical primary standard
InChI	1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
InChI key	MKPLKVHSHYCHOC-AHTXBMBWSA-N
manufacturer/tradename	USP
storage temp.	−20°C

Analysis Note:	These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application:	• Innovative eye drop applications: Travoprost has been incorporated into engineered lipoprotein nanoparticles, showcasing a novel method for drug delivery aimed at enhancing therapeutic efficacy in ocular treatments, particularly for conditions like glaucoma and ocular hypertension (Fukuda et al., 2024 ). • Prostaglandin analogs in glaucoma treatment: The effectiveness and safety of benzalkonium chloride-preserved travoprost eye drops have been critically evaluated, providing insights into their impact on ocular health, particularly on conjunctival goblet cells, which are vital for maintaining eye surface health in glaucoma patients (Nagstrup, 2023 ). • Travoprost liquid nanocrystals: Research into travoprost liquid nanocrystals has demonstrated their potential as a significant advancement in glaucoma therapy, offering improved delivery mechanisms and potentially greater efficacy in reducing intraocular pressure (El-Gendy et al., 2023 ). • Cerebrospinal fluid reabsorption: Studies on prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa reveal new roles for travoprost in physiological processes beyond ocular applications, indicating potential new therapeutic pathways (Pedler et al., 2021 ).
General description:	This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia .
Other Notes:	Sales restrictions may apply.

Symbol	GHS02,GHS07
Signal word	Danger
Hazard statements	H225 - H319
Precautionary statements	P210 - P233 - P240 - P241 - P242 - P305 + P351 + P338
RIDADR	UN 1992 6.1(3) / PGII
WGK Germany	WGK 2
Flash Point(F)	55.4 °F
Flash Point(C)	13 °C

Storage Temp.	−20°C
UNSPSC	41116107

Choose a favorite list for this item:

Catalog Number	Description	Price

		$

Please choose a list :

Continue Shopping

Returns/Order support

Please fill out the form below if you want to request order support from Krackeler Scientific.